To explore how peptides are studied and applied across research settings, visit our Research Library.
Weight loss research is no longer just about how much body weight a compound can remove. The question researchers are now asking, and the one clinicians see playing out in practice, is what happens after people stop.
A landmark 88-week randomized withdrawal trial published in JAMA in January 2024 provides the clearest answer yet for tirzepatide, the once-weekly dual GIP and GLP-1 receptor agonist now at the center of metabolic research. The study enrolled 783 adults with obesity across 70 sites in four countries. Participants began with a 36-week open-label lead-in period, during which they received the maximum tolerated dose of tirzepatide, 10 mg or 15 mg weekly, alongside standard diet and physical activity guidance. The lead-in alone produced an average body weight reduction of 20.9%, consistent with the magnitude observed in earlier phase 3 work on tirzepatide.
Then came the actual question the trial was designed to answer. At week 36, 670 participants who completed the lead-in were randomly assigned to either continue tirzepatide at their established dose or switch to placebo. Mean age was 48, 71% of participants were women, and mean baseline weight was 107.3 kilograms. Both groups were followed for another 52 weeks under double-blind conditions.
The contrast at week 88 was stark. Participants who remained on tirzepatide lost an additional 5.5% of body weight on average during the maintenance period. Participants who switched to placebo regained 14.0% over the same window. The absolute difference between the two groups was 19.4 percentage points, one of the largest separations ever documented in an obesity pharmacotherapy withdrawal design.
What researchers flagged as most important, however, was not the weight number itself. It was the cardiometabolic trajectory. Nearly all of the improvements observed during the lead-in period, including blood pressure, lipids, and glycemic markers, were partially or fully reversed in the group that discontinued. Weight was not the only thing that came back. For a broader look at why this pattern recurs across incretin compounds, see our article on what happens when you stop peptides.
The finding formalizes something researchers had suspected for years. Obesity is increasingly framed as a chronic, relapsing condition rather than a time-limited intervention target, and tirzepatide’s pharmacology fits that framing. The compound is a dual GIP and GLP-1 receptor agonist, meaning its effects on appetite signaling, gastric emptying, and satiety are active only while therapeutic concentrations remain in circulation. Remove the compound, and the same physiological drivers of energy intake that preceded treatment return. This is part of why GLP-1 weight loss plateaus eventually appear even during continued treatment.
A follow-on trial is already underway testing whether a reduced maintenance dose can preserve the results achieved at the maximum tolerated dose. That study is expected to complete in 2026 and will directly compare continued high-dose tirzepatide against a 5 mg reduced-dose arm and placebo, after a 60-week open-label lead-in. If the reduced-dose arm holds weight comparably to the maximum dose, it would reshape both the clinical calculus and the economics of long-term incretin therapy. Researchers comparing tirzepatide against other leading compounds can explore the mechanistic differences in our tirzepatide vs semaglutide overview.
For researchers working with research-grade tirzepatide, the withdrawal data reshape the questions worth asking. The magnitude of weight loss with dual incretin compounds is now well-established. The harder, more interesting questions concern durability. Which participant phenotypes maintain benefit at lower doses. Which rebound most aggressively on discontinuation. Whether combination, alternating, or tapering protocols can preserve results while reducing cumulative exposure. Those questions will define the next phase of metabolic peptide research, and the published data set from this 88-week trial will serve as the reference point every follow-up study compares against.